Safety
Compounded GLP-1 safety and current FDA concerns
Compounded semaglutide and tirzepatide are not FDA-approved medicines. A prescription can be patient-specific, but it still needs an appropriate medical rationale, compliant production, and careful dispensing.
What FDA approval does and does not mean
FDA reviews approved drugs for safety, effectiveness, and quality before marketing. Compounded medicines do not undergo that review. Descriptions such as pharmaceutical-grade, doctor prescribed, or made in a registered facility do not change that approval status.
FDA advises using a compounded drug only when a patient's medical needs cannot be met by an approved drug. Obtain a prescription through a clinician and fill it through a state-licensed pharmacy. These checks should be completed for the actual product, not inferred from a platform's overall reputation.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
The shortage exception changed
FDA's current clarification explains restrictions after the tirzepatide and semaglutide injection shortages were resolved. Section 503A patient-specific compounding and section 503B outsourcing have different conditions; neither is a blanket permission to mass-market essentially copies.
Adding a vitamin, changing a dose slightly, or describing a formula as personalized does not by itself establish that an exception applies. Ask the clinician and pharmacy to explain the medically necessary difference for the patient and the applicable pathway.
Sources: FDA clarification of compounding policies as GLP-1 supply stabilizes
Formulation and dosing concerns
FDA warns against semaglutide salt forms such as sodium and acetate because they differ from the active ingredient in approved drugs. It also reports dosing errors and adverse events associated with unapproved GLP-1 products.
Vials need concentration-specific instructions, and compounded oral products need their own evidence. Do not assume that approved-drug dosing, absorption, storage, or trial outcomes apply to a different formula. Injections with uncertain sourcing or inadequate labeling deserve a pharmacy review before use.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
A practical conversation before treatment
Ask why an approved product cannot meet the medical need, who prescribes, who compounds and dispenses, what ingredients are present, and how the dose is measured. Discuss alternatives, coverage problems, monitoring, and what happens if side effects or a quality concern arise.
This page does not determine whether a particular prescription meets every legal condition or declare an unverified provider's product unlawful. The point is to make the unresolved questions visible and to avoid treating marketing as approval evidence.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss · FDA clarification of compounding policies as GLP-1 supply stabilizes
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.